Madrigal Pharmaceuticals Reports Preliminary Q4 And FY2024 Rezdiffra (Resmetirom) Net Sales Of $100M-$103M And $177M-$180M, Respectively, With Preliminary Cash Balance Of Approximately $931M, And As Of Year-end 2024, More Than 11,800 Patients On Rezdiffra
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.